product name Droxidopa
Description: Droxidopa (also known as L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). Droxidopa is a pro-drug which is structurally similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Droxidopa is well tolerated.
References: Clin Auton Res. 2008 Mar;18 Suppl 1:25-9; Clin Auton Res. 2001 Aug;11(4):235-42.
213.19
Formula
C9H11NO5
CAS No.
23651-95-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
L-DOPS
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398665
| In Vitro |
In vitro activity: Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Droxidopa is well tolerated. Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure. Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Clin Auton Res. 2008 Mar;18 Suppl 1:25-9; Clin Auton Res. 2001 Aug;11(4):235-42. |
Related Posts
product name Droxidopa
Description: Droxidopa (also known as L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). Droxidopa is a pro-drug which is structurally similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Droxidopa is well tolerated.
References: Clin Auton Res. 2008 Mar;18 Suppl 1:25-9; Clin Auton Res. 2001 Aug;11(4):235-42.
213.19
Formula
C9H11NO5
CAS No.
23651-95-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
L-DOPS
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398665
| In Vitro |
In vitro activity: Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Droxidopa is well tolerated. Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure. Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Clin Auton Res. 2008 Mar;18 Suppl 1:25-9; Clin Auton Res. 2001 Aug;11(4):235-42. |